'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Social Anxiety Disorders (SAD) to Central Nervous System Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Social Anxiety Disorders (SAD) to Central Nervous System Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Social Anxiety Disorders (SAD) Therapeutics Clinical Trials 27
Prominent Drugs 29
Clinical Trial Profile Snapshots 30
Appendix 88
Abbreviations 88
Definitions 88
Research Methodology 89
Secondary Research 89
About GlobalData 90
Contact Us 90
Disclaimer 90
Source 91
List of Tables
Social Anxiety Disorders (SAD) Therapeutics, Global, Clinical Trials by Region, 2016* 6
Social Anxiety Disorders (SAD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Social Anxiety Disorders (SAD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2016* 9
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Social Anxiety Disorders (SAD) to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 14
Social Anxiety Disorders (SAD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Social Anxiety Disorders (SAD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Social Anxiety Disorders (SAD) to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 17
Social Anxiety Disorders (SAD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Social Anxiety Disorders (SAD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Social Anxiety Disorders (SAD) Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Social Anxiety Disorders (SAD) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Social Anxiety Disorders (SAD) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Social Anxiety Disorders (SAD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
List of Figures
Social Anxiety Disorders (SAD) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Social Anxiety Disorders (SAD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Social Anxiety Disorders (SAD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2016* 9
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Social Anxiety Disorders (SAD) to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 14
Social Anxiety Disorders (SAD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Social Anxiety Disorders (SAD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Social Anxiety Disorders (SAD) to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 17
Social Anxiety Disorders (SAD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Social Anxiety Disorders (SAD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Social Anxiety Disorders (SAD) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Social Anxiety Disorders (SAD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Social Anxiety Disorders (SAD) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Social Anxiety Disorders (SAD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Social Anxiety Disorders (SAD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 89